Related Experiment Video
Updated: Feb 15, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia
Chetasi Talati1,2, Jeffrey E Lancet1
1Malignant Hematology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Abstract:
Multiple novel therapeutic agents against acute myeloid leukemia (AML) have been evaluated in the past several decades without meaningful clinical improvement in outcomes, especially for AML patients age ≥60, where the overall incidence of AML is highest. Therapeutic options mainly consist of hypomethylating agents, ongoing clinical trials and, less commonly, intensive cytotoxic chemotherapy. CPX-351, a novel liposomal formulation which encapsulates cytarabine and daunorubicin in 5:1 molar ratio, has shown promising efficacy, leading to recent US FDA approval for front-line therapy for patients with therapy-related AML and AML with myelodysplasia-related changes based on a large multicenter Phase III clinical trial. This review summarizes the clinical development of CPX-351 as induction therapy.
Related Concept Videos
Secondary Active Transport
Primary and Secondary Growth in Roots and Shoots
Secondary Healthcare System
Secondary Distribution
In residential areas, 120/240 V single-phase, three-wire service is commonly used for lighting, outlets, and large appliances. Urban areas with high-density loads...
Global Climate Change
Rates of Change

